JP Morgan upgraded Amneal to Overweight, raising its price target to $12, citing strong generics growth and expanding biosimilar adoption. Every week, our Whisper Index uncovers five overlooked ...
BRIDGEWATER, N.J., March 03, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and ...
Amneal reported Q4 sales of $730.52M, up 18% Y/Y, beating estimates, while adjusted EPS of $0.12 missed the $0.15 consensus. 2025 guidance: Revenue of $3B-$3.1B, adjusted EPS of $0.65-$0.70, and ...
BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $31.1 million in its fourth quarter. The Bridgewater, New Jersey-based ...
AMNEAL PHARMACEUTICALS ($AMRX) posted quarterly earnings results on Friday, February 28th. The company reported earnings of $0.12 per share, missing estimates of $0. ...
JPMorgan upgraded Amneal Pharmaceuticals (AMRX) to Overweight from Neutral with a price target of $12, up from $9. The firm cites the Crexont launch being off to a solid start and continued ...
Reports Q4 revenue $731M, consensus $708.07M. “Amneal’s continued success in 2024 demonstrates our ability to drive sustainable growth through disciplined execution, continuous innovation ...